Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB:ACHFF), announced today that cilastatin, the Company’s second drug candidate for preventing acute kidney injury (AKI), will participate in the upcoming investigator led trial entitled “Prevention Of NephroToxin Induced Acute kidney injury with Cilastatin” (PONTIAC). PONTIAC is a 900 patient Phase II trial that will evaluate the efficacy of the dipeptidase-1 inhibitor cilastatin for preventing AKI caused by drugs such as antibiotics, chemotherapeutic agents and radiographic contrast.
Related news for (ACHFF)
- Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)
- Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)